Pegylated interferon-alpha-2b

Pegylated interferon-alpha-2b
Clinical data
ATC code	L03AB10 (WHO) ;
Pharmacokinetic data
Elimination half-life	22-60 hrs
Identifiers
	IUPAC name PEGylated human interferon alpha 2b;
CAS Number	99210-65-8;
DrugBank	BTD00048;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C860H1353N229O255S9
Molar mass	19269.1 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pegylated interferon alfa-2b is a treatment for hepatitis C developed by Schering-Plough, brand name is Peg Intron.

It was approved in January 2001.

Clinical data
ATC code	L03AB10 (WHO)
Pharmacokinetic data
Elimination half-life	22-60 hrs
Identifiers
IUPAC name PEGylated human interferon alpha 2b
CAS Number	99210-65-8
DrugBank	BTD00048
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₈₆₀H₁₃₅₃N₂₂₉O₂₅₅S₉
Molar mass	19269.1 g/mol